| Fan, Jia |
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) |
|
|
| Not yet recruiting | 4 | 600 | NA | Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Unresectable Hepatocellular Carcinoma | 09/25 | 01/27 | | |
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC |
|
|
| Recruiting | 3 | 490 | RoW | IBI310, Sintilimab, Sorafenib | Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 360 | RoW | TACE+Camrelizumab+Apatinib mesylate, TACE | Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 07/24 | 07/26 | | |
| Active, not recruiting | 3 | 908 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo | AstraZeneca, AstraZeneca AB | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
|
|
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2/3 | 178 | RoW | Neoadjuvant treatment | Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy | 12/22 | 12/24 | | |
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2/3 | 668 | RoW | QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab | Qilu Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 09/27 | 09/27 | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC |
|
|
| Active, not recruiting | 2 | 45 | RoW | GP+PD-1+Tight | Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University | Biliary Tract Carcinoma | 01/23 | 12/24 | | |
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer |
|
|
| Completed | 2 | 8 | RoW | TST001 | Shanghai Zhongshan Hospital, Transcenta Holding Limited | Biliary Tract Neoplasms | 05/23 | 05/23 | | |
ZSAB-TransGOLP, NCT05156788: Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | PD-1+Lenvatinib+GEMOX | Shanghai Zhongshan Hospital | Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib | 07/23 | 10/25 | | |
NCT04550624: Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Pembrolizumab Injection [Keytruda], Keytruda, Lenvatinib Mesylate, Lenvima | Shanghai Jiahui International Hospital, Shanghai Zhongshan Hospital | Advanced Biliary Tract Carcinoma | 12/24 | 12/25 | | |
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. |
|
|
| Recruiting | 2 | 117 | RoW | HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo | Shanghai Henlius Biotech | Carcinoma, Hepatocellular | 02/27 | 02/27 | | |
NCT06620848: A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. |
|
|
| Not yet recruiting | 2 | 49 | RoW | HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy | Shanghai Zhongshan Hospital | Biliary Tract Cancer | 12/26 | 06/27 | | |
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | 2 | 55 | RoW | Anlotinib and TQB2450 | Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 10/25 | 12/25 | | |
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma |
|
|
| Terminated | 1/2 | 40 | RoW | Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib | Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
|
|
| Recruiting | 1/2 | 130 | RoW | 3HP-2827 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Solid Tumors With FGFR2 Alterations, Adult | 06/28 | 06/28 | | |
NCT06111326: BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 83 | RoW | BC3402 injection, Durvalumab injection | Biocity Biopharmaceutics Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 05/26 | | |
NCT06584071: A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC |
|
|
| Not yet recruiting | 1/2 | 140 | NA | PM8002, PM1009, atezolizumab, bevacizumab | Biotheus Inc. | HCC, Liver Cancer | 10/26 | 12/27 | | |
NCT05906524: KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 85 | RoW | KD6001, Tislelizumab, Bevacizumab | Shanghai Kanda Biotechnology Co., Ltd. | Advanced HCC, Other Solid Tumors | 04/25 | 12/25 | | |
ZSAB-Calm, NCT05994001: Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody |
|
|
| Recruiting | 1/2 | 96 | RoW | cardonilizumab, PD1 and CTLA-4 bispecific antibody, LM-302, ClAUDIN 18.2-ADC | Shanghai Zhongshan Hospital | Biliary Tract Cancer, Candonilimab, Claudin 18.2 | 08/25 | 08/26 | | |
NCT05701553: Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 20 | RoW | Anti-PD-1/PD-L1, S-Adenosyl-Methionine, SAM | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
BL0006-101, NCT06247657: A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 66 | RoW | BL0006 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 10/24 | 05/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
| Recruiting | 1 | 108 | RoW | IMM27M, IMM2510 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Advanced Solid Tumors, HCC | 01/26 | 01/26 | | |
NCT06757881: IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1 | 18 | RoW | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group), Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） | Shanghai Zhongshan Hospital | HCC | 04/25 | 12/27 | | |
NCT03045731: An US Mathematical Model in Predicting Renal Transplant Rejection |
|
|
| Recruiting | N/A | 180 | RoW | | Shanghai Zhongshan Hospital | Kidney Transplantation | 09/22 | 12/22 | | |
| Not yet recruiting | N/A | 14026 | RoW | | Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 10/22 | 03/23 | | |
| Recruiting | N/A | 14026 | RoW | Multi-cancer early detection test | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Dx Co., Ltd. | Cancer | 12/22 | 03/23 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer with PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Active, not recruiting | N/A | 501 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
| xu, jianmin |
NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer |
|
|
| Recruiting | 3 | 78 | RoW | VIC, Bevacizumab Plus Chemotherapy | Fudan University | Colorectal Cancer | 08/22 | 12/22 | | |
PIDUC, NCT04912258: Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis |
|
|
| Not yet recruiting | 3 | 80 | RoW | Trans arterial chemoembolization with Irinotecan Drug-eluting Beads, Irinotecan Drug-eluting Beads | Fudan University | Colorectal Cancer, Liver Metastases | 12/22 | 06/23 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases |
|
|
| Recruiting | 3 | 308 | RoW | mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab | Fudan University | Colorectal Carcinoma, Liver Metastases | 03/24 | 03/26 | | |
NCT05948072: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM |
|
|
| Not yet recruiting | 3 | 250 | RoW | mFOLFOX6 + Cetuximab, mFOLFOX 6 | Fudan University | Colorectal Cancer, Liver Metastases | 07/26 | 07/26 | | |
NCT05086614: Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer |
|
|
| Recruiting | 3 | 2500 | RoW | Thymosin Alpha1, Thymalfasin | Fudan University | Stage II Colorectal Cancer, Stage III Colorectal Cancer | 03/27 | 03/27 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Cadonilimab + bevacizumab + FOLFOX | Fudan University | Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab | 12/25 | 12/26 | | |
| Recruiting | 2 | 73 | RoW | SHR-1701；Capecitabine；Oxaliplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Locally Advanced Rectal Cancer | 07/24 | 10/26 | | |
| Recruiting | 2 | 23 | RoW | Dostarlimab, GSK4057190A, TSR-042 | GlaxoSmithKline | Neoplasms, Rectal | 12/28 | 03/31 | | |
NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy | Fudan University | Metastatic Colorectal Cancer | 09/25 | 09/25 | | |
NCT06221423: Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Fruquintinib Combined With TAS-102 | Fudan University | Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Carcinoma | 05/24 | 05/24 | | |
NCT06202417: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study |
|
|
| Completed | N/A | 520 | RoW | Fruquintinib, PD1 antibodies, chemotherapy drugs | Fudan University | Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer | 06/22 | 12/23 | | |
NCT06027775: Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases |
|
|
| Completed | N/A | 198 | NA | Targeted agent | Fudan University | Colorectal Cancer Metastatic | 01/23 | 01/23 | | |
NCT06023173: Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases |
|
|
| Completed | N/A | 307 | RoW | Deep radiomics-based fusion model, deep learning model | Fudan University | The Patients With CRLM Who Benefit More From Bevacizumab | 01/23 | 01/23 | | |
| Active, not recruiting | N/A | 1240 | RoW | Robot-assisted resection, Laparoscopic resection | Fudan University | Rectal Carcinoma | 12/23 | 12/23 | | |
DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | N/A | 39 | RoW | DEBIRI Combined With Chemotherapy and Bevacizumab | Fudan University | Colorectal Neoplasms | 01/25 | 05/25 | | |
NCT05873972: Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient |
|
|
| Not yet recruiting | N/A | 100 | RoW | Cetuximab | Fudan University | Colorectal Cancer Liver Metastases | 06/24 | 12/24 | | |
NCT05354674: Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis |
|
|
| Not yet recruiting | N/A | 302 | RoW | Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 07/25 | 07/28 | | |
NCT05881746: Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness |
|
|
| Not yet recruiting | N/A | 176 | RoW | anatomical liver resection, nonanatomical liver resection | Fudan University | Colorectal Carcinoma, Liver Metastases | 07/26 | 07/28 | | |
METHOD-3, NCT05638243: Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program |
|
|
| Recruiting | N/A | 10000 | RoW | | Fudan University | Colorectal Cancer, Colorectal Neoplasms | 02/25 | 09/25 | | |
| Zhou, Jian |
NCT05063071: Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant |
|
|
| Active, not recruiting | 4 | 150 | RoW | Tenofovir Alafenamide 25 MG | Fudan University | HBV, POST LIVER TRANSPLANT | 07/22 | 12/22 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06507436: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
|
|
| Recruiting | 3 | 101 | RoW | Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | 08/25 | 09/25 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04850157: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab, IMRT | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 04/22 | 12/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT05262959: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC |
|
|
| Completed | 2 | 30 | RoW | Donafenib, PD-1, TACE | Shanghai Zhongshan Hospital | Donafenib | 04/24 | 05/24 | | |
NCT06530784: Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 36 | RoW | Cryoablation, PD-1 antibody and bevacizumab | Shanghai Zhongshan Hospital | Carcinoma, Hepatocellular | 12/25 | 05/26 | | |
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies |
|
|
| Recruiting | 2 | 60 | RoW | SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 12/25 | 06/26 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
| Recruiting | 1/2 | 30 | RoW | Toripalimab, Sorafenib | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 10/21 | 12/21 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH |
|
|
| Recruiting | N/A | 190 | RoW | Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations | Xiangya Hospital of Central South University | Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage | 12/24 | 03/25 | | |
NCT06178809: Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 475 | RoW | | Singlera Genomics Inc., Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 04/25 | 12/25 | | |
NCT05200221: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice |
|
|
| Recruiting | N/A | 300 | RoW | | Shanghai Zhongshan Hospital | Donafenib, Hepatocellular Carcinoma | 01/24 | 03/24 | | |
NCT05941286: Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital |
|
|
| Recruiting | N/A | 527 | RoW | CGM system with both glucose predictive alerts and threshold alerts on, CGM system with only glucose threshold alerts on, CGM system with glucose alerts off | Shanghai 6th People's Hospital | Diabetes Mellitus | 08/25 | 09/25 | | |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
NCT06591286: Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control |
|
|
| Recruiting | N/A | 150 | RoW | RT-CGM, SMBG | Shanghai 6th People's Hospital | Diabetes Mellitus, Type 2 | 03/26 | 09/27 | | |
NCT06662630: Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients |
|
|
| Recruiting | N/A | 30 | RoW | High-Frequency Oscillatory Ventilation | Shanghai Zhongshan Hospital | Atelectasis, Acute Respiratory Distress Syndrome, VAP - Ventilator Associated Pneumonia | 10/25 | 10/26 | | |
NCT05087459: Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 141 | RoW | Avatrombopag, Doptelet | Shanghai Zhongshan Hospital | Thrombocytopenia | 06/22 | 07/22 | | |
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers |
|
|
| Completed | N/A | 2430 | RoW | | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc. | Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 06/23 | 07/23 | | |
NCT05707585: Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage |
|
|
| Recruiting | N/A | 2064 | RoW | Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH) | The Second Affiliated Hospital of Dalian Medical University, Fudan University, Zongda Hospital affiliated to Southeast University, West China Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shengjing Hospital, The First Affiliated Hospital of Guangzhou Medical University, Lisen Imprinting Diagnostics, Inc. | Lung Cancer | 01/24 | 07/24 | | |
| Jiang, Wei |
NCT06492460: 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 422 | RoW | Drug：Cisplatin, CDDP Drug | Sun Yat-sen University, Hunan Cancer Hospital, Guilin Medical University, China, Jiangsu Cancer Institute & Hospital, Xiangya Hospital of Central South University | Squamous Cell Carcinoma of Head and Neck | 09/29 | 07/33 | | |
NCT05527470: Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Gemcitabine,Cisplatin, Induction chemotherapy regimen, Intensity-modulated radiation therapy (IMRT), Cisplatin, Concurrent chemotherapy regimen | Wei Jiang, Wuzhou Red Cross Hospital, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Lingshan people's Hospital, Laibin People's Hospital, Nationalities Hospital of Guangxi Zhuang Autonomous Region | Nasopharyngeal Carcinoma | 11/25 | 11/27 | | |
NCT04515602: Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) |
|
|
| Not yet recruiting | 3 | 410 | RoW | Primary debulking surgery, PDS, Neoadjuvant chemotherapy, Neoadjuvant chemotherapy followed by interval debulking surgery, NACT-IDS, PARPi | Shanghai Gynecologic Oncology Group, Obstetrics & Gynecology Hospital of Fudan University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai First Maternity and Infant Hospital | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 01/28 | 01/28 | | |
| Recruiting | 2 | 30 | RoW | Niraparib | Tianjin Huanhu Hospital | Recurrent Glioblastoma | 01/22 | 01/23 | | |
NCT04600817: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
|
|
| Active, not recruiting | 2 | 160 | RoW | TJ107, TJ107 placebo | TJ Biopharma Co., Ltd. | Newly Diagnosed Glioblastoma | 12/24 | 12/24 | | |
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. |
|
|
| Completed | 2 | 34 | RoW | Chidamide, CS055, Envafolimab, KN035 | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 02/23 | 05/24 | | |
| Recruiting | 2 | 200 | RoW | Camrelizumab, PD-1 antibody, Gemcitabine, Gem, Induction Cisplatin, DDP, intensity-modulated radiotherapy, IMRT, Concurrent cisplatin | Wei Jiang, Wuzhou Red Cross Hospital, Guangxi Nanxishan Hospital, Laibin People's Hospital, Lingshan people's Hospital | Nasopharyngeal Carcinoma | 04/25 | 04/26 | | |
| Recruiting | 2 | 167 | RoW | Surgery, secondary cytoreduction, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., third-line therapy, Niraparib, maintenance therapy | Shanghai Gynecologic Oncology Group, Fudan University, Shanghai Jiao Tong University School of Medicine, Zhejiang Cancer Hospital, Sun Yat-sen University | Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 06/25 | 12/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT03131427: China Registry for Genetic / Metabolic Liver Diseases |
|
|
| Recruiting | N/A | 20000 | RoW | Standard of care | Beijing Friendship Hospital, Beijing YouAn Hospital, Henan Provincial People's Hospital, Beijing Ditan Hospital, Hebei Medical University Third Hospital, Peking University First Hospital, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Nanfang Hospital of Southern Medical University, Logistics University of Chinese People's Armed Police Forces, Beijing Anzhen Hospital, West China Second University Hospital of Sichuan University, Jinshan Hospital Fudan University, Fudan University | Genetic/Metabolic Liver Diseases | 04/22 | 04/27 | | |
BESMILE-HF, NCT03180320: Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure ( Study) |
|
|
| Recruiting | N/A | 150 | RoW | BESMILE-HF program, Usual medications | Guangdong Provincial Hospital of Traditional Chinese Medicine | Heart Failure NYHA Class II, Heart Failure NYHA Class III | 12/22 | 12/22 | | |
NCT05176821: Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection |
|
|
| Recruiting | N/A | 186 | RoW | esomeprazole plus amoxicillin, HDDT, amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole, FT | Shanghai Zhongshan Hospital | H. Pylori Infection | 12/22 | 12/22 | | |
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study) |
|
|
| Active, not recruiting | N/A | 88 | RoW | WeFlow-Arch Modeler Embedded Branch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Aortic Arch Aneurysm | 02/25 | 02/29 | | |
NCT06327126: Efficacy and Safety of Single-session Endoscopic Stone Extraction |
|
|
| Completed | N/A | 563 | RoW | two-session ERCP, single-session ERCP | Beijing Friendship Hospital | Choledocholithiasis With Acute Cholangitis | 05/24 | 07/24 | | |
